Skip to main content

Oncology news

12-09-2017 | Breast cancer | Highlight | Article

ESMO 2017

First-line abemaciclib supported for HR+HER2– advanced breast cancer

Results from the MONARCH 3 study give support to first-line use of the oral selective CDK4/6 inhibitor abemaciclib, taken alongside nonsteroidal aromatase inhibitor therapy, in patients with advanced hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.

22-09-2017 | HBV | News | Article

High metabolic risk burden increases HCC risk in HBV patients

A high burden of metabolic risk factors significantly increases the risk for hepatocellular carcinoma among men with hepatitis B virus infection, particularly those who smoke, researchers from Taiwan report.


Gastroenterology 2017; Advance online publication

21-09-2017 | Oncology | News | Article


Bevacizumab biosimilar approved in USA

More details about this decision are just a click away

20-09-2017 | Oncology | News | Article

ESMO 2017 in brief

Cancer vigilance may be warranted for stroke survivors

Survivors of ischemic stroke are more likely to be diagnosed with cancer than the general population, a chart review suggests.

20-09-2017 | Lymphoma | Main feed | News


Copanlisib, low-dose cabazitaxel receive FDA go ahead

Click through to read more on these approvals

Adjuvant Chemotherapy May Extend OS For Locally Advanced Gastro-Oesophageal Cancer Patients

Propensity score-matched analysis points to survival benefit with addition of postoperative chemotherapy to neoadjuvant chemoradiotherapy and surgery for locally advanced gastro-oesophageal cancer Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).

approvalsWatch: Oncology

ESMO 2016 coverage


medwireNews brings you news and conference reports from the ESMO 2016 Congress, held in Copenhagen, Denmark.

Click through to read the full reports of the latest research.

Twitter Icon Follow medwireNews

Click here
image credits